Markov Chain-Guided Graph Construction and Sampling Depth Optimization for EEG-Based Mental Disorder Detection

TL;DR

This paper introduces a Markov Chain-guided graph construction and sampling depth optimization method for EEG data, improving deep GNN performance in mental disorder detection with high accuracy.

Contribution

It proposes a novel graph construction and sampling depth optimization approach using Markov Chains tailored for EEG data analysis in mental disorder detection.

Findings

Achieved 100% accuracy on schizophrenia dataset with minimal data

Over 99% accuracy on depression dataset

Effective in distinguishing healthy controls from patients

Abstract

Graph Neural Networks (GNNs) have received considerable attention since its introduction. It has been widely applied in various fields due to its ability to represent graph structured data. However, the application of GNNs is constrained by two main issues. Firstly, the "over-smoothing" problem restricts the use of deeper network structures. Secondly, GNNs' applicability is greatly limited when nodes and edges are not clearly defined and expressed, as is the case with EEG data.In this study, we proposed an innovative approach that harnesses the distinctive properties of the graph structure's Markov Chain to optimize the sampling depth of deep graph convolution networks. We introduced a tailored method for constructing graph structures specifically designed for analyzing EEG data, alongside the development of a vertex-level GNN classification model for precise detection of mental disorders. In order to verify the method's performance, we conduct experiments on two disease datasets using a subject-independent experiment scenario. For the Schizophrenia (SZ) data, our method achieves an average accuracy of 100% using only the first 300 seconds of data from each subject. Similarly, for Major Depressive Disorder (MDD) data, the method yields average accuracies of over 99%. These experiments demonstrate the method's ability to effectively distinguish between healthy control (HC) subjects and patients with mental disorders. We believe this method shows great promise for clinical diagnosis.